The COPD devices market is projected to expand from US$ 8,849.16 million in 2022 to US$ 12,877.43 million by 2030, with an anticipated compound annual growth rate (CAGR) of 4.8% during the period from 2022 to 2030.

Chronic obstructive pulmonary disease (COPD) encompasses a range of conditions that lead to airflow obstruction and difficulties in breathing. This group of diseases includes emphysema and chronic bronchitis, both of which can result in lung damage and excessive mucus production. Common symptoms associated with COPD are persistent cough, often accompanied by phlegm, shortness of breath, wheezing, and fatigue. The primary contributors to the development of COPD are smoking and exposure to air pollution. Individuals suffering from COPD face an increased risk of developing additional health complications. The Centers for Disease Control and Prevention (CDC) reports that approximately 16 million Americans are affected by this debilitating condition, which significantly impairs their ability to breathe. Various inhalation devices are available for managing COPD, including metered-dose inhalers (MDIs), dry-powder inhalers (DPIs), soft mist inhalers (SMIs), and small-volume nebulizers (SVNs). Each type of device offers distinct features that must be considered when determining the most suitable treatment for individual patients.

The introduction of smart inhalers presents new avenues for growth within the COPD devices market.

Smart inhalers are designed to assist individuals with COPD in adhering to their medication regimens by tracking the timing and dosage of their inhalations through smartphone applications. This data can be invaluable for healthcare providers, allowing them to assess the effectiveness of prescribed treatments, tailor COPD management strategies to address the underlying causes of symptom exacerbation, and implement early warning systems that alert patients when they should seek medical attention. This innovative technology has the potential to transform the traditional approach to COPD management, reducing the need for routine check-ups and alleviating the burden on healthcare systems such as the National Health Service (NHS). Smart inhalers are particularly beneficial for older adults, who may struggle with consistent inhalation techniques due to age-related respiratory muscle weakness. These devices, often equipped with sensors, can connect to standard inhalers to monitor medication usage. With Bluetooth capabilities, they can seamlessly sync with computers or mobile devices, facilitating automatic data transfer. In India, the demand for smart inhalers is on the rise, driven by the increasing incidence of respiratory illnesses, including COPD, and prevalent smoking behaviors.

Chronic obstructive pulmonary disease is characterized by chronic inflammation of the lungs, leading to obstructed airflow. Symptoms typically include difficulty breathing, persistent cough, mucus production, and wheezing. The condition is primarily caused by prolonged exposure to harmful gases or particulate matter, most commonly from cigarette smoke. Individuals with COPD are at a heightened risk for serious health issues, including heart disease and lung cancer. The American Lung Association identifies COPD as the leading cause of death in the United States, with over 12 million diagnosed cases reported in 2022. Globally, approximately 8.5 million adults were diagnosed with COPD between 2019 and 2020. The World Health Organization (WHO) noted that COPD was the third leading cause of death worldwide in 2021. The high mortality associated with COPD is often due to acute exacerbations that can lead to respiratory muscle failure, resulting in patients losing their ability to breathe independently, which can ultimately lead to death from systemic infections or asphyxia. Furthermore, the Burden of Obstructive Lung Disease (BOLD) report from 2020 predicts that global mortality from COPD could rise to 5.4 million deaths annually by 2060. The increasing prevalence of COPD worldwide is a significant driver of growth in the COPD devices market.

Geographically, the COPD devices market is divided into several regions: North America (including the US, Canada, and Mexico), Europe (comprising the UK, Germany, France, Italy, Spain, Russia, and other European nations), Asia Pacific (including China, Japan, India, South Korea, Australia, Southeast Asia, and the rest of the region), the Middle East & Africa (covering the UAE, Saudi Arabia, South Africa, and other countries), and South & Central America (including Brazil, Argentina, and others). North America currently leads the global COPD devices market in terms of growth. However, the Asia Pacific region is anticipated to experience the highest CAGR in the COPD devices market from 2022 to 2030, driven by the rising incidence of respiratory disorders. In the United States, COPD represents a significant health challenge, primarily attributed to smoking, which remains the leading cause of the disease. The CDC estimates that around 14.8 million adults in the US are living with COPD.

Additionally, the population aged 65 and older in the United States was reported to be 54.1 million, accounting for 16% of the total population, with projections indicating this figure could rise to 21.6% by 2040. This aging demographic is more vulnerable to chronic respiratory diseases, suggesting that the growing elderly population will further stimulate the demand for respiratory inhalers in the coming years. Moreover, favorable reimbursement policies are expected to create significant opportunities for the expansion of the COPD devices market.

Key sources utilized in the preparation of this report on the COPD devices market include ClinicalTrails.com, the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), and the National Health Services (NHS).